Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
59 studies found for:    NIAID | Recruiting | allergy OR asthma OR diabetes OR transplant OR multiple sclerosis OR psoriatic arthritis OR lupus
Show Display Options
Rank Status Study
1 Recruiting Natural History and Genetics of Food Allergy and Related Conditions
Conditions: Food Allergy;   Loeys-Dietz Syndrome
Intervention:
2 Recruiting Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
Conditions: Asthma;   Eosinophilia;   Helminthiasis;   Hypersensitivity;   Parasitic Disease
Intervention:
3 Recruiting Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide
Condition: Chronic Granulomatous Disease
Interventions: Drug: Pre-Transplant Conditioning Medications;   Other: Haploidentical Cellular Infusion;   Drug: Post-Trasnplant Medications;   Radiation: Total Body Irradiation
4 Recruiting High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
Condition: X-Linked Chronic Granulomatious Disease
Interventions: Drug: Campath;   Drug: Busulfan;   Other: allogeneic peripheral blood allograft infusion;   Drug: cyclophosphamide
5 Recruiting Cockroach Nasal Allergen Challenge Pilot
Conditions: Asthma;   Cockroach Hypersensitivity
Intervention: Biological: Glycerinated German Cockroach Allergenic Extract
6 Recruiting Rituximab and Belimumab for Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
7 Recruiting Registry for Asthma Characterization and Recruitment 2
Condition: Asthma
Intervention:
8 Recruiting Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus;   SLE
Interventions: Drug: Mycophenolate Mofetil;   Drug: Hydroxychloroquine or Chloroquine;   Drug: Prednisone
9 Recruiting Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
Condition: Asthma
Intervention:
10 Recruiting Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy
Conditions: Cat Allergy;   Cat Hypersensitivity
Interventions: Biological: AMG 157;   Biological: Cat Immunotherapy;   Biological: Cat Immunotherapy Placebo;   Biological: AMG 157 Placebo
11 Recruiting Autologous Polyclonal Tregs for Lupus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic
Intervention: Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
12 Recruiting Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Condition: Inherited Immune Deficiencies
Interventions: Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
13 Recruiting Type 1 Diabetes Extension Study
Conditions: Type 1 Diabetes;   Diabetes Mellitus
Intervention:
14 Recruiting Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Condition: Kidney Transplant
Interventions: Biological: Infliximab;   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Biological: Thymoglobulin;   Drug: Acetaminophen;   Drug: Loratadine;   Biological: Placebo for Infliximab;   Drug: Prednisone;   Drug: Diphenhydramine
15 Recruiting Post‐Traumatic Stress Symptoms (PTSS) in Transplant Recipients
Conditions: Solid Organ Transplant Recipients;   Parent(s)/Guardian of Referenced Transplant Recipients
Intervention: Other: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
16 Recruiting B Cell Induction in Pediatric Lung Transplantation
Condition: Lung Transplant
Interventions: Biological: Rituximab (Rituxan®);   Biological: Placebo
17 Recruiting BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
Condition: Kidney Transplantation
Interventions: Biological: Antithymocyte globulin (ATG);   Drug: Fludarabine;   Drug: Low dose Pre-transplant cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Methylprednisolone;   Biological: Bone Marrow;   Drug: MESNA;   Drug: Mycophenolate mofetil (MMF);   Drug: Prednisone;   Drug: Filgrastim;   Drug: High dose post-transplant cyclophosphamide
18 Recruiting Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
Conditions: Liver Transplant;   Liver Transplantation
Intervention: Procedure: Immunosuppression withdrawal
19 Recruiting Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Conditions: Type 1 Diabetes Mellitus;   New-onset Type 1 Diabetes Mellitus;   T1DM;   T1D
Interventions: Drug: Tocilizumab (TCZ);   Drug: Placebo
20 Recruiting Fel d 1 Peptide Immunotherapy Clinical Trial
Conditions: Cat Allergy;   Cat Hypersensitivity
Interventions: Drug: Cat-PAD;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.